VTYX - What's Going On With Autoimmune/Inflammatory Disorder-Focused Ventyx Biosciences On Monday? | Benzinga
Ventyx Biosciences Inc (NASDAQ:VTYX) shares are trading lower after the company provided clinical and pipeline updates on Monday during its virtual investor event.
“With these compelling clinical results and support from our recent PIPE financing, we are announcing a pipeline reprioritization, with internal resources to be focused on advancing our portfolio of potential best-in-class NLRP3 inhibitors in high-value indications with a substantial unmet medical need,” said Raju Mohan, CEO.
The company is developing two NLRP3 inhibitors:
- VTX3232 (CNS-penetrant NLRP3 Inhibitor): The company completed a Phase 1 single- and multiple-ascending dose trial of VTX3232 in adult healthy volunteers. VTX3232 was well-tolerated, with no dose-limiting toxicities identified. All treatment-emergent adverse events were ...